What Is Donanemab? Eli Lilly's Alzheimer's Drug Gets Delayed Decision From FDA
Lilly(US:LLY) Forbes·2024-03-08 16:27ToplineThe FDA has delayed a decision on whether it will approve donanemab, Eli Lilly’s closely watched new Alzheimer’s drug, despite promising study results that showed it could significantly slow cognitive and functional decline in early-symptomatic Alzheimer’s patients, the pharmaceutical company announced Friday.FILE - A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis on ... [+] April 26, 2017. The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth quar ...